Empirical Finance LLC Trims Stake in United Therapeutics Co. (NASDAQ:UTHR)

Empirical Finance LLC lowered its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 47.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,297 shares of the biotechnology company’s stock after selling 2,076 shares during the period. Empirical Finance LLC’s holdings in United Therapeutics were worth $810,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC raised its stake in United Therapeutics by 0.8% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock valued at $1,761,000 after purchasing an additional 39 shares in the last quarter. MBM Wealth Consultants LLC raised its position in shares of United Therapeutics by 1.9% during the 4th quarter. MBM Wealth Consultants LLC now owns 2,151 shares of the biotechnology company’s stock valued at $775,000 after buying an additional 41 shares in the last quarter. First Citizens Bank & Trust Co. lifted its holdings in shares of United Therapeutics by 1.8% during the 3rd quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock worth $961,000 after acquiring an additional 48 shares during the last quarter. Signaturefd LLC grew its position in United Therapeutics by 8.8% in the third quarter. Signaturefd LLC now owns 633 shares of the biotechnology company’s stock worth $227,000 after acquiring an additional 51 shares in the last quarter. Finally, UMB Bank n.a. increased its stake in United Therapeutics by 4.9% in the fourth quarter. UMB Bank n.a. now owns 1,101 shares of the biotechnology company’s stock valued at $388,000 after acquiring an additional 51 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

NASDAQ UTHR opened at $345.64 on Tuesday. United Therapeutics Co. has a 1 year low of $210.64 and a 1 year high of $417.82. The stock has a market capitalization of $15.43 billion, a PE ratio of 15.18, a PEG ratio of 0.92 and a beta of 0.57. The business’s 50-day moving average is $362.37 and its 200 day moving average is $358.13.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Argus boosted their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. The Goldman Sachs Group boosted their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. Finally, TD Cowen increased their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $382.08.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the sale, the director now directly owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. The trade was a 83.84 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Nilda Mesa sold 255 shares of the stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the transaction, the director now directly owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 111,864 shares of company stock worth $41,036,365. 11.90% of the stock is currently owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.